The agenda for the 17 September 2014 Transparency Commission is now available. The Commission will consider the following new medicines and new uses for existing medicines:

• Granupas (para-aminosalicylic acid) - new medicine
• Olysio (simeprevir sodium) - new medicine
• Vimizim (elosulfase alfa) - new medicine
• Vipidia (alogliptin benzoate) - new medicine
• Vipdomet (alogliptin benzoate with metformin hydrochloride) - new combination product